News | Renal Denervation | August 23, 2016

Technavio Reports Renal Denervation Devices on the Rise

Prevalence of hypertension, rise of minimally invasive procedures and new technological innovations expected to drive growth through 2020

Technavio report, renal denervation devices, 2015

August 23, 2016 — Technavio analysts forecast the global renal denervation market to grow at a compound annual growth rate (CAGR) of close to 12 percent during the forecast period, according to their latest report.

The research study covers the present scenario and growth prospects of the global renal denervation market for 2016-2020. The demand for these devices is high. However, the market is growing slowly as clinical trials have failed to prove the safety and efficacy of many renal denervation devices. Technavio said the market will grow with the U.S. Food and Drug Administration (FDA) approval of Medtronic's SYMPLICITY HTN-4 renal denervation device after the completion of associated clinical study in February 2017.

Europe accounted for more than 57 percent of the market in 2015 due to the CE mark approval of a few of its renal denervation devices.

Technavio healthcare and life sciences analysts highlight the following three factors that are contributing to the growth of the global renal denervation market:

  • Widespread prevalence of hypertension;
  • Use of minimally-invasive procedures; and
  • Technological innovations to simplify renal denervation.

Widespread prevalence of hypertension

According to Barath Palada, a lead analyst at Technavio for medical devices research, “Unhealthy diet, stress and physical inactivity can lead to conditions such as hypertension, hypercholesterolemia, coronary artery disease and diabetes.”

Hypertension or high blood pressure can cause ischemia and stroke. With each passing year, the prevalence of hypertension is rising worldwide. In 2013, the Centers for Disease Control and Prevention (CDC) estimated that more than 30 percent of the global adult population had hypertension. Furthermore, in 2013, the organization estimated that 70 million adults in the United States had high blood pressure, accounting for one in every three adults in the country).

In 2015, the National Health Service estimated that about 500,000 people in the United Kingdom had drug-resistant hypertension. In many cases, blood pressures were higher than 140/90 mmHg and could not be managed even with three or more anti-hypertensives. These cases require the use of renal denervation devices to manage hypertension.

Use of minimally-invasive procedures

Physicians worldwide are emphasizing the use of minimally-invasive techniques in surgical procedures. A rise in the use of minimally-invasive, catheter-based endovascular procedure for managing hypertension has led to higher adoption of renal denervation devices. These devices are safe and effective, and reduce cardiometabolic risks. They also help reduce the length of hospital stays, as the procedure can be completed in about an hour, and people undergoing the procedure only need to stay in the hospital for six more hours or so. This reduces direct and indirect hospitalization costs.

Advances in the procedure have led to the development of a radiofrequency catheter-based approach for renal denervation. Radiofrequency therapy is applied to the endoluminal surface of renal arteries via an electrode located at the tip of the catheter. This type of renal denervation procedure causes no trauma and minimizes recovery time.

Technological innovations to simplify renal denervation

“Manufacturers are developing new catheter-based devices to simplify the technicality and shorten the duration of renal denervation procedures, which augurs well for the growth of the market,” said Barath.

  • St. Jude Medical's EnligHTN multi-electrode renal denervation system uses a basket catheter that contains four electrodes, one in each strut of the basket. These struts expand to establish contact between the electrodes and vessel walls. Each electrode activates separately for 90 seconds. The catheter is retrieved and rotated 45 degrees and a second set of ablations are made. Advances in technology have led to the development of intuitive touch-screen generators that reduce the duration of procedures. The device's features allow for simultaneous ablations, which reduces total ablation time from 24 minutes to four minutes.
  • Kona Medical’s Surround Sound Renal Denervation System delivers ablation energy to the posterior portion of a patient's body, which eliminates the need for catheterization. The device delivers ultrasound energy, which surrounds the artery and ablates the nerves located in the vicinity of the vessel.

Other vendor offerings include the Vessix renal denervation system from Boston Scientific Corp. and a percutaneous renal denervation system from ReCor Medical Inc.

For more information: www.technavio.com

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...